Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report

Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling a...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrado, Egle, Saladino, Antonino, Morgante, Giusy, Mignano, Antonino, Nugara, Cinzia, Novo, Giuseppina, Coppola, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455401/
https://www.ncbi.nlm.nih.gov/pubmed/32884751
http://dx.doi.org/10.1002/ccr3.2655
Descripción
Sumario:Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.

Ejemplares similares